Objective
to compare the 2-year clinical outcome of everolimus-eluting stent (Xience, EES) and zotarolimus-eluting stent (ZES, Resolute) with biolimus-eluting stent (Biomatrix, BES)
Study
open label, multicentre randomised non-inferiority trial (1:1:1). (Non-inferiority margin 3.8%)
Population
all-comer patients
Endpoints
composite of cardiac death, target-vessel MI and clinically indicated target lesion revascularisation at 24 months
Conclusion
Biolimus-eluting is non-inferior to either everolimus-eluting or zotarolimus-eluting stent at 24 months in all-comers. Caution: prematurely terminated
Youn et al. Circulation Cardiovascular Interv. 2020;13e 008525 (March)